Abstract
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.
Highlights
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD)
Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs
Однако высокая частота развития неблагоприятных реакций (НР), отсутствие контроля за их приемом и настороженности пациентов в отношении возможных осложнений существенно сдерживают применение нестероидным противовоспалительным препаратам (НПВП) при Хронический болевой синдром (ХБС)
Summary
The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). На фоне введения БТА отмечены уменьшение боли с 8 до 3 см по ВАШ, а также улучшение функции суставов на 40%.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
